Clinical Trials Browser

Multiple Myeloma × Organization and Administration × Clear all

NCT02519452 2025-05-23

A Study of Daratumumab With the Addition of Recombinant Human Hyaluronidase (rHuPH20) for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma

Phase 1 Completed

Multiple Myeloma